公开(公告)号：US12121553B2

公开(公告)日：2024-10-22

申请号：US17160132

申请日：2021-01-27

申请人： General Probiotics, Inc.

发明人： Yiannis John Kaznessis ,  Kathryn Gayle Kruziki ,  Dimitrios Nikolaos Sidiropoulos

IPC分类号： A61K35/741 ,  A23K10/18 ,  A23K50/75 ,  A61K38/16 ,  A61P31/04 ,  C07K14/315 ,  C12N1/20 ,  C12N15/70

CPC分类号： A61K35/741 ,  A23K10/18 ,  A23K50/75 ,  A61K38/164 ,  A61P31/04 ,  C07K14/315 ,  C12N1/205 ,  C12N15/70

摘要： This invention relates, at least in part, to engineered antimicrobial probiotics for the prevention or treatment of Clostridia perfringens-induced necrotic enteritis in animals and related methods. In an embodiment, a composition for treatment of chickens is included. The composition can include a bacterium originally isolated from the small intestinal tract of healthy chickens and can be genetically engineered with two exogenous polynucleotides. A first exogenous polynucleotide can include a heterologous promoter and a polynucleotide that encodes an antimicrobial protein. A second exogenous polynucleotide can include a heterologous promoter and a polynucleotide that encodes proteins that function to secrete the antimicrobial protein to the extracellular environment. In an embodiment, the antimicrobial peptide can be effective in killing C. perf. inside the gastrointestinal tract of chickens.

公开(公告)号：US20240342272A1

公开(公告)日：2024-10-17

申请号：US18755430

申请日：2024-06-26

申请人： David Kotlyar

发明人： David Kotlyar

IPC分类号： A61K39/215 ,  A61K39/00 ,  C07K14/315

CPC分类号： A61K39/215 ,  C07K14/315 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/543

摘要： Disclosed is a pharmaceutical composition to prevent transmission of a pathogen (i.e., including SARS-CoV-2 amongst other pathogens), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize a pathogen (i.e., including SARS-CoV-2 amongst other pathogens), wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to a pathogen (i.e., including SARS-CoV-2 amongst other pathogens) but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

公开(公告)号：US12071455B2

公开(公告)日：2024-08-27

申请号：US17458131

申请日：2021-08-26

申请人： The Regents of the University of California ,  BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY

发明人： Andrew R. Hagen ,  Cheryl A. Kerfeld ,  Nancy B. Sloan ,  Markus Sutter ,  Bryan H. Ferlez

IPC分类号： C07K14/195 ,  B01D15/36 ,  B01D15/38 ,  C07K1/22 ,  C07K14/315 ,  C12N15/62

CPC分类号： C07K14/195 ,  B01D15/363 ,  B01D15/3804 ,  C07K1/22 ,  C07K14/315 ,  C12N15/62 ,  C07K2319/70

摘要： The present invention provides for a fusion protein comprising (1) a bacterial microcompartment (BMC) shell protein comprising one or more subunit, and (2) a first component of a specific-binding pair, operably linked to the BMC shell protein such that the first component faces (i) a lumen (inside) side, or (ii) outside of a BMC shell formed incorporating the fusion protein and the fusion protein does not disrupt or prevent the folding of the BMC shell protein or the ability of the BMC shell protein to integrate with other BMC shell proteins into a BMC shell; wherein the first component is capable of forming a stable or irreversible interaction with a second component of the specific-binding pair.

公开(公告)号：US20240225024A9

公开(公告)日：2024-07-11

申请号：US18546950

申请日：2022-02-23

申请人： Chr. Hansen A/S

发明人： Jesper BROEND ,  Sonja BLOCH ,  Kim Ib SOERENSEN

IPC分类号： A23C9/123 ,  C07K14/315 ,  C12N1/20 ,  C12N9/12 ,  C12N9/90

CPC分类号： A23C9/1238 ,  C07K14/315 ,  C12N1/205 ,  C12N9/1205 ,  C12N9/90 ,  C12R2001/46

摘要： The present invention relates to a composition comprising one or more novel Streptococcus thermophilus strain(s), and the use of said composition for producing a fermented product such as a dairy product with e.g. an increased sweetness. The invention also relates to novel Streptococcus thermophilus strain(s) as such.

公开(公告)号：US20240130384A1

公开(公告)日：2024-04-25

申请号：US18546950

申请日：2022-02-23

申请人： Chr. Hansen A/S

发明人： Jesper BROEND ,  Sonja BLOCH ,  Kim Ib SOERENSEN

IPC分类号： A23C9/123 ,  C07K14/315 ,  C12N1/20 ,  C12N9/12 ,  C12N9/90

CPC分类号： A23C9/1238 ,  C07K14/315 ,  C12N1/205 ,  C12N9/1205 ,  C12N9/90 ,  C12R2001/46

摘要： The present invention relates to a composition comprising one or more novel Streptococcus thermophilus strain(s), and the use of said composition for producing a fermented product such as a dairy product with e.g. an increased sweetness. The invention also relates to novel Streptococcus thermophilus strain(s) as such.

公开(公告)号：US20240016970A1

公开(公告)日：2024-01-18

申请号：US18327916

申请日：2023-06-02

申请人： MICROSINTESIS INC.

发明人： Monica Angela Cella ,  Sarah M. Curtis ,  Jonathon Patrick Roepke

IPC分类号： C07K14/335 ,  C07K14/315 ,  A61K35/747 ,  A61K35/745 ,  A61P31/04 ,  A61L27/54 ,  A61L29/16

CPC分类号： C07K14/335 ,  C07K14/315 ,  A61K35/747 ,  A61K35/745 ,  A61P31/04 ,  A61L27/54 ,  A61L29/16 ,  A61L2300/404 ,  A61L2300/25

摘要： Provided are peptides that are derived from probiotic bacteria that may be useful for preventing and/or treating enteric infections or non-enteric infections in a subject. The peptides may also find use for reducing the virulence of enteric infections or non-enteric infections in a subject. Also provided are compositions of the peptides and compositions comprising culture fractions of the probiotic bacteria.

公开(公告)号：US20230382981A1

公开(公告)日：2023-11-30

申请号：US18201595

申请日：2023-05-24

申请人： GRIFFITH UNIVERSITY

发明人： Michael F. GOOD ,  Manisha PANDEY ,  Michael Raymond BATZLOFF

IPC分类号： C07K16/12 ,  A61K9/00 ,  A61K38/16 ,  A61K39/116 ,  A61K39/09 ,  A61K47/64

CPC分类号： C07K16/1271 ,  A61K9/0019 ,  A61K38/16 ,  A61K39/116 ,  A61K39/092 ,  A61K47/646 ,  C07K14/315

摘要： A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.

公开(公告)号：US20230375562A1

公开(公告)日：2023-11-23

申请号：US18029086

申请日：2021-09-28

申请人： GERONMED, CO. LTD

发明人： Byung Cheon LEE ,  Hae Min LEE

IPC分类号： G01N33/68 ,  C07K14/315 ,  C07K14/35

CPC分类号： G01N33/6815 ,  C07K14/315 ,  C07K14/35 ,  G01N2800/7009 ,  C07K2319/60

摘要： A fluorescent protein sensor capable of quantitatively measuring oxidation degree of methionine residues of a specific protein, and a use thereof. Specifically, a fluorescent biosensor recombinant protein in which an MsrB protein, a cpYFP protein, a thioredoxin 3 protein, a linker protein and a G protein are linked in this order, and which is capable of quantitatively measuring the oxidation degree of methionine residues of a target protein; a fluorescent biosensor comprising same; a method for measuring oxidation degree of methionine residues of a target protein; and an information providing method for diagnosis of oxidative stress-associated diseases; and a method for screening for a therapeutic agent for oxidative stress-associated diseases. A recombinant protein for a fluorescent biosensor for accurately and quantitatively measuring, through the detection of a specific change in fluorescence, oxidation degree of methionine residues of a specific protein, but not all proteins, even in a mixed biological sample.

公开(公告)号：US20230287377A1

公开(公告)日：2023-09-14

申请号：US18308336

申请日：2023-04-27

申请人： Sigma-Aldrich Co., LLC

发明人： Fuqiang Chen

IPC分类号： C12N9/22 ,  C07K14/205 ,  C07K14/31 ,  C07K14/315 ,  C12N15/113

CPC分类号： C12N9/22 ,  C07K14/205 ,  C07K14/31 ,  C07K14/315 ,  C12N15/113 ,  C07K2319/09

摘要： Engineered Cas9 systems are disclosed herein.

公开(公告)号：US11732033B2

公开(公告)日：2023-08-22

申请号：US16640819

申请日：2018-08-22

申请人： GRIFFITH UNIVERSITY

发明人： Michael F. Good ,  Manisha Pandey ,  Michael Raymond Batzloff

IPC分类号： A61K39/09 ,  A61K38/16 ,  A61K39/116 ,  A61K9/00 ,  A61K47/64 ,  C07K14/315 ,  C07K16/12 ,  A61K39/385 ,  A61K39/00

CPC分类号： C07K16/1271 ,  A61K9/0019 ,  A61K38/16 ,  A61K39/092 ,  A61K39/116 ,  A61K47/646 ,  C07K14/315

摘要： A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.